论文部分内容阅读
粘膜表面免疫接种技术的应用将能显著促进未来疫苗接种的进展。现在应能最大限度地增强许多疫苗的抗原性,促使它们与适宜的淋巴组织发生作用,藉以诱导保护性细胞和体液应答。应用现有技术已能研制仅需接种2剂的粘膜疫苗。最有希望的粘膜疫苗是活疫苗,但仍有许多工作要做,新型微囊包裹的释放系统和佐剂使死疫苗成为粘膜免疫的合理选择。粘膜疫苗应被研制成联合疫苗,粘膜疫苗的概念应取代口服疫苗。
The application of mucosal surface immunization technology will be able to significantly promote the future progress of vaccination. It should now be possible to maximize the antigenicity of many vaccines and to promote their interaction with appropriate lymphoid tissues in order to induce protective cellular and humoral responses. It has been possible to develop mucosal vaccines which require administration of only two doses using the prior art. The most promising mucosal vaccine is a live vaccine, but much remains to be done, and newer microencapsulated delivery systems and adjuvants make the death vaccine a reasonable choice for mucosal immunity. Mucosal vaccine should be developed into a combination vaccine, mucosal vaccine should replace the concept of oral vaccine.